← ANALYST RATINGS · TIPRANKS

Evommune, Inc. (EVMN): analyst forecast and price target

$5.17 −12.82% close 16.10.26 · market cap $215M · General · Biotechnology IWM 0.01%
Price targets and ratings of

Analyst consensus

Strong Buy

8 Buy1 Hold0 Sell

Ratings of 9 analysts in the last 3 months · top analysts only

12-month forecast

$23.43+353.2% upside

Based on 9 price targets given in the last 3 months, the average target is $23.43, the highest $30.00, the lowest $18.00. The average is +353.2% from the last price of $5.17.

$10.00$20.00$30.00Jan 26AprJulOctJan 27AprJulOctHigh$30.00Average$23.43Low$18.00
Highest target $30.00 Average target $23.43 Lowest target $18.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Name not given — $8.00 Hold +54.7% Initiated 12.10.26on TipRanks 06:05 −3.1%next day −2.8%
Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% H.C. Wainwright — Hold — Reiterated 05.10.26on TipRanks 06:50 −4.6%next day −1.2% · 5 days −9.4%
Prakhar Agrawal★★★★★★★★★★#1817 · hits 40% · avg +16.0% Cantor Fitzgerald — Buy — Reiterated 17.09.26on TipRanks Sep 18 07:45 −1.1%next day +2.9% · 5 days −6.9%
Thomas Smith★★★★★★★★★★#45 · hits 57% · avg +51.1% Leerink Partners $28.00 → $22.00−21.4% Buy +325.5% Assigned 10.09.26on TipRanks Sep 9 08:35 −16.7%next day −2.0% · 5 days −12.5%
Kaveri Pohlman★★★★★★★★★★#1640 · hits 40% · avg +12.9% Clear Street $28.00 → $23.00−17.9% Buy +344.9% Reiterated 09.09.26on TipRanks 19:55 −2.0%next day −1.0% · 5 days −11.9%
Alex Thompson CFA★★★★★★★★★★#60 · hits 73% · avg +50.6% Stifel Nicolaus $30.00 Buy +480.3% Reiterated 09.09.26on TipRanks 10:35 −16.7%next day −2.0% · 5 days −12.5%
Serge Belanger★★★★★★★★★★#674 · hits 49% · avg +14.9% Needham $28.00 Buy +441.6% Reiterated 09.09.26on TipRanks 09:35 −16.7%next day −2.0% · 5 days −12.5%
Martin Auster★★★★★★★★★★#1128 · hits 51% · avg +16.1% Raymond James $18.00 Buy +248.2% Reiterated 09.09.26on TipRanks 08:30 −16.7%next day −2.0% · 5 days −12.5%
Kostas Biliouris★★★★★★★★★★#9060 · hits 41% · avg −0.1% Oppenheimer $26.00 Buy +402.9% Reiterated 09.09.26on TipRanks 07:50 −16.7%next day −2.0% · 5 days −12.5%
Matt Phipps★★★★★★★★★★#2652 · hits 48% · avg +4.8% William Blair — Hold — Reiterated 09.09.26on TipRanks 05:30 −16.7%next day −2.0% · 5 days −12.5%
Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% RBC Capital $29.00 → $21.00−27.6% Buy +306.2% Reiterated 08.09.26on TipRanks Sep 9 07:30 +7.2%next day −16.7% · 5 days −22.5%
Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% Evercore ISI $22.00 Buy +325.5% Reiterated 10.08.26on TipRanks 08:40 0.0%next day +1.3% · 5 days +1.3%
Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% Morgan Stanley $26.00 Buy +402.9% Assigned 10.08.26on TipRanks 08:21 0.0%next day +1.3% · 5 days +1.3%
Andreas Argyrides★★★★★★★★★★#1658 · hits 46% · avg +10.2% Chardan Capital $42.00 Buy +712.4% Initiated 23.01.26on TipRanks Jan 22 08:20 −0.3%next day −0.1% · 5 days +13.9%

The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included

Best analysts covering Evommune, Inc.

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Judah Frommer★★★★★★★★★★Morgan Stanley · #2495
Hits 56%168 of 302 Average return +5.3%
1 year Alex Thompson CFA★★★★★★★★★★Stifel Nicolaus · #60
Hits 73%153 of 209 Average return +50.6%
2 years Alex Thompson CFA★★★★★★★★★★Stifel Nicolaus · #60
Hits 73%153 of 209 Average return +50.6%

Most profitable

3 months Judah Frommer★★★★★★★★★★Morgan Stanley · #2495
Hits 56%168 of 302 Average return +5.3%
1 year Alex Thompson CFA★★★★★★★★★★Stifel Nicolaus · #60
Hits 73%153 of 209 Average return +50.6%
2 years Alex Thompson CFA★★★★★★★★★★Stifel Nicolaus · #60
Hits 73%153 of 209 Average return +50.6%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $24.00 at a price of $8.26 (+190.6%); now: $22.40 at $5.17 (+333.3%).

$10.00$20.00Sep 15Oct 1Oct 15Top analysts$23.43Average target$22.40Price$5.17

PriceAverage targetTop analysts’ target

Recommendation trend · top analysts

0510Oct 25Nov31Dec71Jan 2691Feb9Mar7Apr9May71Jun61Jul63Aug1013Sep914Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy9766109
Buy000011
Hold011334
Sell000000

Earnings and sales forecast

Next report: 10.12.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $-0.83 (from $-1.02 to $-0.67). Last quarter: $-0.89.

Best top-analyst consensus in the sector · General

STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
About Evommune, Inc.
  • CEO: Luis C. Pena
  • Employees: 48
  • 1841 Page Mill Road, Palo Alto, CA, 94304, US
  • www.evommune.com

Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.

Data from the stock’s TipRanks forecast page, read 4 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗